Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited on its €15 million growth capital investment in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate) and Amelly Kok (Associate) from our Corporate Team. Fruytier Lawyers in Business advised on matters of Dutch law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
News & Insights
NDAs – an update following publication of the EHRC guidance
When should employers take legal advise on how to use confidentiality agreements (non-disclosure agreements) legitimately?
Charles Russell Speechlys advises the Raymond Brown Group, backed by Elysian Capital
The Raymond Brown Group sold its waste management business, RBWS Ltd to Collard Group Limited.
Charles Russell Speechlys advises the shareholders of Henshin Group Limited on the investment by Veos S.P.A.
Charles Russell Speechlys advised the shareholders of Henshin Group Limited on a major investment by Veos S.P.A.